Ultra-small phospholipid nanoparticles in the treatment of combined hyperlipidemia: a randomized placebo-controlled clinical trial

Alexander Archakov , Valery Kukharchuk, Andrey Lisitsa, Elena Ponomarenko, Yulia Romashova, Tatiana Pleshakova, Elena Yarovaya, Vladimir Kutsenko, Maria Guseva, Valery Beregovykh, Olga Ipatova, Marina Zubareva, Elena Tikhonova, Sergei Ivanov, Farid Bedretdinov, Sergey Markin

Abstract


Background and purpose: Combined hyperlipidemia is associated with an increased risk of cardiovascular events. This clinical trial investigated phospholipovit (essential phospholipids, Institute of Biomedical Chemistry, Moscow, Russia), an ultra-small phospholipid nanoparticle (micelles), targeted to phospholipids of HDL in lowering non-HDL-cholesterol (non-HDL-C) and triglycerides (TG) levels in patients with combined hyperlipidemia and moderate cardiovascular risk.

Experimental approach: A randomized, double-blinded, placebo-controlled phase II trial was conducted on 100 patients. Phospholipovit or placebo was randomly administered orally (500 mg) 2 times a day for 12 weeks. The primary endpoint was the percent change of non-HDL-C from baseline to 12 weeks of exposure.

Findings/Results: Treatment with phospholipovit resulted in a mean non-HDL-C reduction of 13.2% versus 4.3% compared with placebo. The absolute decrease in non-HDL-C was -23.2 (-48.7 - 7.0) mg/dL versus -7.3 (-17.0 - 12.0) mg/dL, significantly. The therapeutic target of non-HDL-C less than 130 mg/dL (3.4 mmol) was achieved in 15 of 39 patients (38.5%) in the phospholipovit group versus 2 of 41 patients (4.9%) in the placebo group OR 11.8 (2.4 - 116). Significant reduction in TG, apolipoprotein B, total cholesterol, and very low-density lipoprotein cholesterol levels was also observed. There were no changes in the liver and kidney functions, vital signs, or electrocardiography. There were no serious adverse events.

Conclusion and implications: Phospholipovit significantly reduced non-HDL-C, TG, and atherogenic lipoproteins in patients with combined hyperlipidemia and moderate cardiovascular risk. It can be used as an add-on therapy to statins.

 

 


Keywords


Combined hyperlipidemia; Non-HDL-C; Phospholipid nanoparticles (micelles); TG.

Full Text:

PDF

References


Mach F, Baigent C, Catapano AL, Koskinas KC, Casula M, Badimon L, et al. 2019 ESC/EAS guidelines for the management of dyslipidaemias: lipid modification to reduce cardiovascular risk: the task force for the management of dyslipidaemias of the european society of cardiology (ESC) and european atherosclerosis society (EAS). Eur Heart J. 2020;41(1):111-188.DOI: 10.1093/eurheartj/ehz455.

Sarwar N, Sandhu MS, Ricketts SL, Butterworth AS, Di Angelantonio E, Boekholdt SM, et al. Triglyceride-mediated pathways and coronary disease: collaborative analysis of 101 studies. Lancet. 2010;375(9726):1634-1639.DOI: 10.1016/S0140-6736(10)60545-4.

Do R, Willer CJ, Schmidt EM, Sengupta S, Gao C, Peloso GM, et al. Common variants associated with plasma triglycerides and risk for coronary artery disease. Nat Genet. 2013;45(11):1345-1352.DOI: 10.1038/ng.2795.

Miller M, Stone NJ, Ballantyne C, Bittner V, Criqui M, Ginsberg HN, et al. Triglycerides and cardiovascular disease: a scientific statement from the american heart association. Circulation. 2011;123(20):2292-2333.DOI: 10.1161/CIR.0b013e3182160726.

Marston NA, Giugliano RP, Kyung AI, Silverman MG, O’Donoghue ML, Wiviott SD, et al. Association between triglyceride lowering and reduction of cardiovascular risk across multiple lipid-lowering therapeutic classes: a systematic review and meta-regression analysis of randomized controlled trials. Circulation. 2019;140(16):1308-1317.DOI: 10.1161/CIRCULATIONAHA.119.041998.

Ouimet M, Barrett TJ, Fisher EA. HDL and reverse cholesterol transport. Circ Res. 2019;124(10):1505-1518.DOI: 10.1161/CIRCRESAHA.119.312617.

Rader DJ, Alexander ET, Weibel GL, Billheimer J, Rothblat GH. The role of reverse cholesterol transport in animals and humans and relationship to atherosclerosis. J Lipid Res. 2009;50(Suppl):S189-S194.DOI: 10.1194/jlr.R800088-JLR200.

Rohatgi A, Khera A, Berry JD, Givens EG, Ayers CR, Wedin KE, et al. HDL cholesterol efflux capacity and incident cardiovascular events. N Engl J Med. 2014;371(25):2383-2393.DOI: 10.1056/NEJMoa1409065.

Archakov AI, Guseva MK, Uchaikin VF, Tikhonova EG, Ipatova OM. Medical forms of phospholipid preparations and methods for their preparation. United States Patent, 2014. No. US8680061B2. Available in: https://patents.google.com/patent/US8680061B2/en.

Lokhov PG, Maslov DL, Balashova EE, Trifonova OP, Medvedeva NV, Torkhovskaya TI, et al. Mass spectrometry analysis of blood plasma lipidome as method of disease diagnostics, evaluation of effectiveness and optimization of drug therapy. Biomed Khim. 2015;61(1):7-18.DOI: 10.18097/pbmc20156101007.

Kudinov VA, Torkhovskaya TI, Zakharova TS, Morozevich GE, Artyushev RI, Zubareva MYu, et al. High-density lipoprotein remodeling by phospholipid nanoparticles improves cholesterol efflux capacity and protects from atherosclerosis. Biomed Pharmacother. 2021;141:111900,1-11.DOI: 10.1016/j.biopha.2021.111900.

Archakov AI, Guseva MK, Uchaikin VF, Ipatova OM, Tikhonova EG, Shironin AV. Nanoform of phospholipid preparation for oral use (sachet) and method of its obtaining (versions). Russian Patent, 2010. No. RU2463057C2. Available in: https://patents.google.com/patent/RU2463057C2/ru.

Friedewald WT, Levy RI, Fredrickson DS. Estimation of the concentration of low-density lipoprotein cholesterol in plasma, without use of the preparative ultracentrifuge. Clin Chem. 1972;18:499-502.DOI: 10.1093/clinchem/18.6.499.

Signorelli A. DescTools: tools for descriptive statistics. R package version 0.99.20.CRAN. 2017.

Kukharchuk VV, Konovalov GA, Susekov AV, Sergienko IV, Semenova AE, Gornyakova NB, et al. Diagnosis and correction of lipid metabolism disorders with the aim of prevention and treatment of atherosclerosis. Russ J Cardiol. 2012;4(96):1-32.

Bhatt DL, Steg PG, Miller M, Brinton EA, Jacobson TA, Ketchum SB, et al. Cardiovascular risk reduction with icosapent ethyl for hypertriglyceridemia. N Engl J Med. 2019;380(1):11-22.DOI: 10.1056/NEJMoa1812792.

Nicholls SJ, Lincoff AM, Garcia M, Bash D, Ballantyne CM, Barter PJ, et al. Effect of high-dose omega-3 fatty acids vs corn oil on major adverse cardiovascular events in patients at high cardiovascular risk. The STRENGTH randomized clinical trial. JAMA. 2020;324(22):2268-2280.DOI: 10.1001/jama.2020.22258.

Tardif JC, Karwatowska-Prokopczu E, Amour ES, Ballantyne ChM, Shapiro MD, Moriarty PM, et al. Apolipoprotein C-III reduction in subjects with moderate hypertriglyceridemia and at high cardiovascular risk. Eur Heart J. 2022;43(14):1401-1412.DOI: 10.1093/eurheartj/ehab820.

Duan Y, Gong K, Xu S, Zhang F, Meng X, Han J. Regulation of cholesterol homeostasis in health and diseases: from mechanisms to targeted therapeutics. Signal Transduct Target Ther. 2022;7(1):265,1-29.DOI: 10.1038/s41392-022-01125-5.

Nicholls SJ, Puri R, Ballantyne CM, Jukema JW, Kastelein JJP, Koenig W, et al. Effect of infusion of high-density lipoprotein mimetic containing recombinant apolipoprotein A-I Milano on coronary disease in patients with an acute coronary syndrome in the MILANO-PILOT trial: a randomized clinical trial. JAMA Cardiol. 2018;3(9):806-814.DOI: 10.1001/jamacardio.2018.2112.

Nicholls SJ, Andrews J, Kastelein JJP, Merkel B, Nisen SE, Ray KK, et al. Effect of serial infusions of CER-001, a prebeta high-density lipoprotein mimetic, on coronary atherosclerosis in patients following acute coronary syndromes in the CER-001 atherosclerosis regression acute coronary syndrome trial: a randomized clinical trial. JAMA Cardiol. 2018;3(9):815-822.DOI: 10.1001/jamacardio.2018.2121.

Tardif JC, Gregoire J, L'Allier PL, Ibrahim R, Lesperance J, Heinonen TM, et al. Effects of reconstituted high-density lipoprotein infusions on coronary atherosclerosis: a randomized controlled trial. JAMA. 2007;297(15):1675-1682.DOI: 10.1001/jama.297.15.jpc70004.

Nissen SE, Tsunoda T, Tuzcu EM, Schoenhagen P, Cooper CJ, Yasin M, et al. Effect of recombinant ApoA-I Milano coronary atherosclerosis in patients with acute coronary syndromes: a randomized controlled trial. JAMA. 2003;290(17):2292-2300.DOI: 10.1001/jama.290.17.2292.

Study to investigate CSL112 in subjects with acute coronary syndrome (AEGIS-II). ClinicalTrials.gov Identifier: NCT03473223.

Day C. Obstacles to the clinical investigation of phospholipids. Artery. 1975;1:1-2.

Tchoua U, Gillard BK, Pownall HJ. HDL superphospholipidation enhances key steps in reverse cholesterol transport. Atherosclerosis. 2010;209(2):430-435.DOI: 10.1016/j.atherosclerosis.2009.10.002.

Paavola T, Kuusisto S, Jauhiainen M, Kakko S, Kangas-Kontio T, Metso J, et al. Impaired HDL2-mediated cholesterol efflux is associated with metabolic syndrome in families with early onset coronary heart disease and low HDL-cholesterol level. PLoS ONE. 2017;12(2): e0171993,1-15.DOI: 10.1371/journal.pone.0171993.

Luo Y, Guo Y, Wang H, Yu M, Hong K, Li D, et al. Phospholipid nanoparticles: therapeutic potentials against atherosclerosis via reducing cholesterol crystals and inhibiting inflammation. EBioMedicine. 2021;74:103725,1-16.DOI: 10.1016/j.ebiom.2021.103725.

Meikle PJ, Formosa MF, Mellett NA, Jayawardana KS, Giles C, Bertovic DA, et al. HDL phospholipids, but not cholesterol distinguish acute coronary syndrome from stable coronary artery disease. J Am Heart Assoc. 2019;8(11):e011792,1-42.DOI: 10.1161/JAHA.118.011792.


Refbacks

  • There are currently no refbacks.


Creative Commons LicenseThis work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License which allows users to read, copy, distribute and make derivative works for non-commercial purposes from the material, as long as the author of the original work is cited properly.